Washington (SmartAboutHealth) - Shares in drug maker Acorda have jumped after news broke that the FDA had granted priority review status to their experimental MS drug called Fampridine-SR.

This is great news for the company as back in March the FDA had refused to accept the filing application for the drug due to various “formatting” issues which Acorda have since took care of.

The FDA granted priority status to the drug because of its positive results in clinical trials.

A priority review, means that the agency will review the drug for possible approval much sooner than they would normally, thus Acorda will know of their decision by as early as October 22nd.

Multiple sclerosis is a type of disease in which the body’s own immune system turns on itself, attacking the protective covering of the nerves in the spine and brain.

It is estimated that more than 400,000 Americans live with MS.